This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Last month, the FDA published a draft guidance document relating to potential fines that may be incurred if submitters of data and trial information on clinicaltrials.gov either do not report clinical trial results, or misreport findings.
The document, “Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,” explains that under section 303(f)(3) of the Federal Food, Drug and Cosmetic Act (FD&C Act), the FDA is authorized to assess civil money penalties against responsible parties and/or submitters of applications for drug products, biologics, and devices.
The guidance also answered some general questions, such as how the FDA intends to identify whether an organization or someone has failed to submit required clinical trial registration and/or results to the data bank or submitted false information. The FDA plans to identify such violations through evidence collected during inspections, as well as through complaints received by the agency.
If the agency has deemed that a party has failed to comply with regulation, it “intends to send the responsible party a Preliminary Notice of Noncompliance (Pre-Notice) Letter, which describes the potential violation and requests that the responsible party review the record in the ClinicalTrials.gov data bank and make any necessary corrections within 30 days,” read the document. If the violation has not been addressed in the 30 days, the agency will then send a Notice of Noncompliance, which allows the party an additional 30 days to remedy the situation.
Should a civil money penalty be assessed, the statutory maximum penalties under the FD&C Act are no more than $10,000 for all violations adjudicated in a single proceeding. In addition, if a violation is not corrected within the 30 days following notification of a violation, an organization can be fined up to, but not more than, $10,000 per day the violation continues.
This guidance document comes after AllTrials, an international initiative, launched a tracking tool in February 2018 that publicly discloses which research entities have not reported data from clinical trials.
Included in the announcement of the initiative was an open letter to FDA Commissioner Scott Gottlieb, MD, that noted that the FDA has the power to sanction such violators and institute fines against clinical trial sponsors that fail to report trial results, and urged the Commissioner to do just that.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.